NSCLC

Browse all NSCLC
How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

NSCLC

How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MD, Estelamari Rodriguez, MD, MPH, Helena Yu, MD

New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

NSCLC

New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MD, Joshua Sabari, MD

Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

NSCLC

Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Estelamari Rodriguez, MD, MPH, Helena Yu, MD, Joshua Sabari, MD

SCLC

Browse all SCLC
Key Takeaways From IMforte for Clinicians Treating ES-SCLC

SCLC

Key Takeaways From IMforte for Clinicians Treating ES-SCLC

Ticiana Leal, MD, Stephen Liu, MD, Isabel Preeshagul, DO, MBS, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Sequencing Lurbinectedin in ES-SCLC with CNS Involvement

SCLC

Sequencing Lurbinectedin in ES-SCLC with CNS Involvement

Ticiana Leal, MD, Stephen Liu, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Managing Lurbinectedin Adverse Events in ES-SCLC Maintenance Therapy

SCLC

Managing Lurbinectedin Adverse Events in ES-SCLC Maintenance Therapy

Isabel Preeshagul, DO, MBS, Stephen Liu, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Clinical Relevance of IMforte Survival Data in ES-SCLC

SCLC

Clinical Relevance of IMforte Survival Data in ES-SCLC

Ticiana Leal, MD, Stephen Liu, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD